Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment
By
Zhengwei Tan
Jinyu Hu
Baodong Ye
Wenbin Liu
July 16, 2026
Clinical Scorecard: Acute Gastrointestinal Graft Versus Host Disease: Insights from Pathogenesis to Targeted Prevention and Treatment Strategies
At a Glance
Category Detail
Condition Acute Gastrointestinal Graft Versus Host Disease (GI-aGVHD) Key Mechanisms Donor T-cell-mediated epithelial damage, microbiota dysbiosis, and barrier disruption. Target Population Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Care Setting Hematology/Oncology
Key Highlights
GI tract is the most severely affected organ in aGVHD with the highest non-relapse mortality. Microbiota dysbiosis is linked to the onset and severity of aGVHD. The MAGIC algorithm aids in biomarker-driven risk stratification. Emerging therapies include ruxolitinib, vedolizumab, and fecal microbiota transplantation (FMT). Novel interventional modalities are being explored to synergize microbiota-directed approaches with immunomodulation. Guideline-Based Recommendations
Diagnosis
Utilize the MAGIC biomarker framework for risk stratification. Management
Consider targeted agents such as ruxolitinib and vedolizumab. Monitoring & Follow-up
Monitor for signs of dysbiosis and epithelial barrier disruption. Risks
Grade II-IV aGVHD occurs in 35%-46% of patients by 6 months. Patient & Prescribing Data
Patients with hematological disorders receiving allo-HSCT.
Shift towards precision medicine with microbiota-immune interventions.
Clinical Best Practices
Implement strategies to restore eubiosis and reinforce epithelial barrier function. Utilize multi-omics approaches to understand the pathogenesis of GI-aGVHD. Related Resources & Content
